Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 17/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145146 | 1.00 | CASP1 (0.58) | CASP1DPP4KCNH2DPP7CTSK | |
| SCHEMBL9003099 | 1.00 | CASP1 (0.58) | CASP1DPP4KCNH2DPP7CTSK | |
| SCHEMBL9003092 | 1.00 | CASP1 (0.58) | CASP1DPP4KCNH2DPP7CTSK | |
| SCHEMBL25185922 | 0.99 | CASP1 (0.59) | CASP1DPP4KCNH2DPP7CTSK | |
| SCHEMBL7140119 | 0.90 | ALDH1A1 (0.53) | CASP1DPP4KCNH2DPP7 | |
| SCHEMBL7140126 | 0.90 | ALDH1A1 (0.53) | CASP1DPP4KCNH2DPP7 | |
| SCHEMBL25186498 | 0.88 | MEN1 (0.56) | CASP1 | |
| SCHEMBL6793150 | 0.88 | DPP4 (0.58) | DPP4KCNH2DPP7CTSK | |
| SCHEMBL25186534 | 0.87 | CASP1 (0.53) | CASP1CTSK | |
| SCHEMBL25185732 | 0.86 | CASP1 (0.55) | CASP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | CASP1 2183/4885DPP4 647/4885KCNH2 4240/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CASP1 3026/4885DPP4 1867/4885KCNH2 4164/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CASP1 3026/4885DPP4 1867/4885KCNH2 4164/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CASP1 3026/4885DPP4 1867/4885KCNH2 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.